Table 10.
Total costs variations of Case 2 with accord to the change values of doses per vial (|I|).
| doses/vial (|I|) | 3 | 5 | 7 | 9 | ||||
|---|---|---|---|---|---|---|---|---|
| Days | DES-NLT | DES-LT | DES-NLT | DES-LT | DES-NLT | DES-LT | DES-NLT | DES-LT |
| 1 | 2088.08 | 2240.44 | 268.215 | 325.65 | -490.07 | -475.02 | -997.25 | -957.61 |
| 2 | 3914.24 | 4188.05 | 406.62 | 587.08 | -1361.60 | -1292.96 | -1910.02 | -1891.92 |
| 3 | 5775.54 | 6182.97 | 536.31 | 835.80 | -2261.98 | -2147.51 | -2882.86 | -2853.89 |
| 7 | 13138.70 | 13992.30 | 1095.02 | 1886.50 | -5836.76 | -5562.89 | -6725.16 | -6704.70 |
| 10 | 18650.31 | 19909.26 | 1535.53 | 2655.17 | -8426.21 | -8065.46 | -9617.88 | -9653.23 |
| 20 | 37054.73 | 39428.50 | 2956.62 | 5229.66 | -17362.00 | -16538.70 | -19076.40 | -19136.90 |
| 30 | 55388.43 | 59055.24 | 4345.75 | 7814.31 | -26242.40 | -25019.90 | -28581.00 | -28713.60 |
Cases where LT outperformed NLT are in bold. Minus values indicate revenue.